Grant: Engage Plus Grants for Colleges
C.E.G.E.P. Lévis-Lauzon
$12,500.00
New parenteral formulation for the management of postoperative pain
EF 2019-20
Résumé
Recent studies have highlighted the value of COX2 inhibitors as alternatives to opioids for the management of postoperative pain and, in particular, the use of Celecoxib. Due to its very low water solubility Celebrex is only available in tablet, precluding its use during and immediately after surgery when tablet formulations cannot be administered. Altus Formulation is a pharmaceutical company specialized in the development of innovative drug delivery systems. Among their various delivery platforms, the SmartCelle technology enables the parenteral delivery of highly insoluble drugs. A previous study, conducted at our facility highlighted the potential of the technology, demonstrating the analgesic potential of the novel soluble formulation in the plantar incision postoperative pain model. This project aims to pursue the preclinical work surrounding the development and the validation of the novel Celecoxib soluble formulation by determining the effective dose 50 of the micellar formulation and evaluating the synergetic potential of the co-administration of Celecoxib and the CB2 receptor agonist Hu-308.
Programme
Engage Plus Grants for Colleges
Bénéficiaire
Emplacement
Quebec, Canada
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
542232-2019
Name nom
Fortier, Isabelle
Department département
Siège social
Organization id
21757
Institution établissement
C.E.G.E.P. Lévis-Lauzon
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2019
Award amount
12500
Program id
CEGP2
Program name en
Engage Plus Grants for Colleges
Program name fr
Subvention d'engagement partenarial Plus pour les collèges
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
1561
Committee name en
Applied Research and Development Grants
Committee name fr
Subventions de recherche et développement appliquée
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
6404
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Pharmacology
Research subject fr
Pharmacologie
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
New parenteral formulation for the management of postoperative pain
Keyword
NSERC
Application summary
Recent studies have highlighted the value of COX2 inhibitors as alternatives to opioids for the management of postoperative pain and, in particular, the use of Celecoxib. Due to its very low water solubility Celebrex is only available in tablet, precluding its use during and immediately after surgery when tablet formulations cannot be administered. Altus Formulation is a pharmaceutical company specialized in the development of innovative drug delivery systems. Among their various delivery platforms, the SmartCelle technology enables the parenteral delivery of highly insoluble drugs. A previous study, conducted at our facility highlighted the potential of the technology, demonstrating the analgesic potential of the novel soluble formulation in the plantar incision postoperative pain model. This project aims to pursue the preclinical work surrounding the development and the validation of the novel Celecoxib soluble formulation by determining the effective dose 50 of the micellar formulation and evaluating the synergetic potential of the co-administration of Celecoxib and the CB2 receptor agonist Hu-308.
